Marlana M. Orloff

Marlana M. Orloff

Oncology
1101 Chestnut Street
Floor 14
Philadelphia, PA 19107

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

A Phase II Trial of Defactinib Combined with Avutometinib in Patients with Metastatic Uveal Melanoma.

A Phase II Trial of Defactinib Combined with Avutometinib in Patients with Metastatic Uveal Melanoma.

Journal: Cancers
Published: April 28, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2026

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Journal: Cancers
Published: November 27, 2025

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion.

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion.

Journal: Journal of vascular and interventional radiology : JVIR
Published: July 16, 2025

Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

Journal: The oncologist
Published: March 24, 2025

Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma.

Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma.

Journal: Journal of clinical medicine
Published: March 20, 2025

Percutaneous Hepatic Perfusion Melphalan Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in a Patient with Metastatic Uveal Melanoma.

Percutaneous Hepatic Perfusion Melphalan Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in a Patient with Metastatic Uveal Melanoma.

Journal: Case reports in oncology
Published: February 12, 2025

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

Journal: Annals of surgical oncology
Published: January 02, 2025

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.

Journal: Journal of cancer research and clinical oncology
Published: November 22, 2024

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 30, 2024

Proceedings of the seventh annual Women in Melanoma Conference.

Proceedings of the seventh annual Women in Melanoma Conference.

Journal: Therapeutic advances in medical oncology
Published: July 22, 2024

Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.

Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.

Journal: Annals of surgical oncology
Published: July 18, 2024
Showing 1-12 of 50

Last Updated: 09/26/2026